Dorton Katina 4

What Happened Dorton Katina, a director of TScan Therapeutics (TCRX), was granted a derivative award on 2026-05-20 covering 67,000 shares. The Form 4 reports an acquisition amount of $0.00, indicating no cash payment at grant; the award is described in the filing as an option.

Key Details

• Transaction date: 2026-05-20; Form filed: 2026-05-22 (appears timely).
• Award: option covering 67,000 shares, reported acquisition price $0.00 (no cash paid at grant).
• Shares owned after transaction: not specified in the provided filing.
• Footnote: the option vests in full upon the earlier of (i) May 20, 2027 or (ii) the next annual meeting of stockholders, subject to continued service by the reporting person.
• Transaction type code: A (award/grant).

Context This is a compensation-related option grant to a board member, not an open-market purchase or sale. Such awards are common for director compensation and do not necessarily signal immediate buying/selling intent. As a derivative grant, the award will only convert to equity if and when vested and exercised per the terms above.